May 7, 2015.
The Asia-Pacific (APAC) treatment market for psoriasis will almost double in value, from $690 million in 2014 to $1.2 billion by 2021, according to a report from GBI Research.
Psoriasis Therapeutics in Asia-Pacific Markets says that the growth will be driven by a rising treatment population and the emergence of new competitive drug products, particularly biologics, which are expected to be approved during the forecast period.
“Recently approved Cosentyx from Novartis and Alzumab from Biocon … are expected to achieve good market penetration by 2021," said GBI Research analyst Rishikesh Mandilwar, adding that promising late-stage pipeline mAbs, such as brodalumab and ixekizumab are also anticipated to be launched during the forecast period. These treatments will be competitors for already-launched secukinumab, as they all target the same molecule.
However, GBI Research’s report also states that the loss of market exclusivity for some of the leading blockbuster biologics over the forecast period represents a significant obstacle to growth. “Humira, Enbrel, and Remicade, which are potential TNF inhibitors and have the major share of the psoriasis market globally, are expected to have a lower market share in the APAC region due to the new launches and greater acceptance of biosimilars, especially in India and China," explained Mandilwar.